Finance

Lists
Q2 2026 earnings • released • EPS beat +21.91% • Revenue beat +0.85%
See results
GMED:NYSE
Globus Medical Inc
$82.35
+1.57%
(+1.27) 1D
$82.35
0.00% (0.00)
After hours
Closed: Aug 7, 4:00:09 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GMED...
Open
$88.12
High
$88.12
Low
$80.71
Mkt. cap
11.18B
Avg. vol.
1.71M
Volume
3.30M
P/E ratio
19.18
52-wk high
$101.40
52-wk low
$54.15
EPS
$4.29
Beta
0.95
Shares outstanding
113.24M
No. of employees
6K
Open
$88.12
High
$88.12
Low
$80.71
Mkt. cap
11.18B
Avg. vol.
1.71M
Volume
3.30M
P/E ratio
19.18
52-wk high
$101.40
52-wk low
$54.15
EPS
$4.29
Beta
0.95
Shares outstanding
113.24M
No. of employees
6K
News stories
From sources across the web
Profile
Globus Medical, Inc. is a publicly traded orthopedic medical device company headquartered in Audubon, Pennsylvania, United States. Globus is focused on the design, development, and commercialization of products that enable surgeons to promote healing in patients with musculoskeletal disorders. Wikipedia
About Globus Medical Inc
CEOKeith Pfeil
Employees6K
Founded2003
Headquarters-
SectorMedical device
Analyst ratings
Based on 13 analysts giving stock ratings to GMED in the past 3 months
Strong buy
Buy
10
Hold
3
Sell
0
12-month forecast
Based on 13 Wall Street analysts offering 12 month price targets for GMED in the last 3 months.
Highest
Current $82.35
$123.00 (+49.36%)
Average
$104.09 (+26.40%)
Lowest
$82.00 (-0.43%)
Analyst
Recommendation
Action
Price target
Projected
Date
Travis Steed
Bank of America Securities
Buy
Maintained
-
-
08/07/2026
Caitlin Roberts
Canaccord Genuity
Buy
Maintained
$115.00
+39.6%
08/06/2026
Thomas Stephan
Stifel Nicolaus
Hold
Maintained
$85.00
+3.2%
08/07/2026
Vik Chopra
BMO Capital
Buy
Reiterated
$94.00
+14.1%
08/07/2026
Richard Newitter
Truist Financial
Buy
Reiterated
$100.00
+21.4%
08/07/2026
Matthew O'Brien
Piper Sandler
Buy
Maintained
$100.00
+21.4%
08/07/2026
Ryan Zimmerman
BTIG
Hold
Maintained
-
-
08/07/2026
David Saxon
Needham
Buy
Reiterated
$117.00
+42.1%
08/07/2026
Kendall Au
RBC Capital
Buy
Maintained
$115.00
+39.6%
08/06/2026
Rishi Jaluria
RBC Capital
Buy
Maintained
$115.00
+39.6%
08/06/2026
Shagun Singh Chadha
RBC Capital
Buy
Maintained
$115.00
+39.6%
08/06/2026
Larry Biegelsen
Wells Fargo
Buy
Maintained
$99.00
+20.2%
08/07/2026
Mathew Blackman
TD Cowen
Buy
Maintained
$115.00
+39.6%
08/06/2026
Unknown Analyst
UBS
Hold
Initiated
$82.00
-0.4%
07/28/2026
Patrick Wood
UBS
Hold
Initiated
$82.00
-0.4%
07/28/2026
Unknown Analyst
BMO Capital
Buy
Initiated
$94.00
+14.1%
07/09/2026
Matt Miksic
Barclays
Buy
Maintained
$123.00
+49.4%
05/11/2026
Caitlin Cronin
Canaccord Genuity
Buy
Reiterated
$115.00
+39.6%
05/08/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$1.34 / $1.10
+21.91%beat
Revenue / Est. (USD)
789.61M / 782.98M
+0.85%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
769.05M
826.42M
759.85M
789.61M
Cost of goods sold
246.13M
254.62M
234.07M
241.44M
Cost of revenue
246.13M
254.62M
234.07M
241.44M
Research and development expenses
38.07M
36.16M
36.51M
36.32M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
284.19M
304.78M
297.77M
286.82M
Operating expense
352.10M
370.30M
363.81M
352.70M
Total operating expenses
598.23M
624.93M
597.87M
594.14M
Operating income
170.82M
201.49M
161.98M
195.47M
Other non operating income
1.54M
865.00K
2.25M
1.17M
EBT including unusual items
143.99M
169.23M
157.07M
189.82M
EBT excluding unusual items
173.65M
198.52M
167.55M
202.85M
Income tax expense
25.03M
28.64M
32.77M
38.25M
Effective tax rate
17.38%
16.92%
20.86%
20.15%
Other operating expenses
-
-
-
-
Net income
118.97M
140.59M
124.30M
151.57M
Net profit margin
15.47%
17.01%
16.36%
19.20%
Earnings per share
1.18
1.28
1.12
1.34
Interest and investment income
1.46M
3.31M
5.43M
7.07M
Interest expense
-
-
-
-
Net interest expenses
1.46M
3.31M
5.43M
7.07M
Depreciation and amortization charges
-
-
-
-
EBITDA
242.02M
270.31M
231.93M
264.87M
Gain or loss from assets sale
2.31M
4.09M
2.45M
3.11M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
Google apps